Oncology Pipeline

Below is our current pipeline for identifying new oncology combination therapy opportunities. It covers 6 oncology areas, and over 70 assets from approx 30 biopharmas/biotechs.

 

Our pipeline demonstrates the ability of our AI-driven drug discovery platform (ALaSCA) to rapidly identify actionable combination therapy options. Combination therapies that progress through this pipeline will be ready for pre-clinical toxicology validation.

​

For a background to our technology and to explore a recent finding with ATRi and ABL1i, please click here. 

​

Please reach out us if you are interested in partnering on any of our pipeline.